Why the study?
Clinical data on hepatitis C virus (HCV) treatment rates in the United States are sparse.
What are the treatment rates and factors associated with direct-acting antiviral therapy among privately insured patients with Hepatitis C in the US?
Population
133 348 privately insured patients with HCV in the US
Design
Retrospective cohort study
Authors
Loading...
Suboptimal 65% DAA treatment rates with post-2019 declines signal persistent care gaps; leaves open need for strategies to boost uptake in insured populations.
What are the treatment rates and factors associated with direct-acting antiviral therapy among privately insured patients with Hepatitis C in the US?
Despite the high efficacy of direct-acting antivirals, less than two-thirds of insured US patients with viremic HCV receive treatment, with rates declining significantly during the COVID-19 pandemic.
Nguyen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: